FindTrial
Sign In

Use of three different drugs for reduction in severity of COVID-19 disease using Arterial Stiffness as a clinical marker

Comparing efficacies of Combinations of Vitamin D3 and Magnesium,Cilnidipine and Telmisartan therapies for reduction in severity of COVID-19 disease using Arterial Stiffness as a clinical marker:A Randomized, Parallel group Comparative Study. - ASCOTH Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/032385
Enrollment
160
Registered
2021-03-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Vitamin D Group with age normalized increase in Pulse wave velocity between 364-580 cm/sec (Arterial stiffness level: 20 Severe non ventilated patients in this group will receive vitami

Sponsors

AIIMS Patna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: RT PCR proved COVID-19 positive patients admitted in AIIMS Patna Age >= 18 years

Exclusion criteria

Exclusion criteria: 1. Patients with severe CAD 2. Congestive heart failure(CHF) 3. Stage II hypertension 4. Hypotension 5. Patients on insulin, Diabetic Neuropathy, 6. Diabetic Keto acidosis 7. Stroke and peripheral arterial disorder 8. Pre-existing Cardiovascular disease 9. Recent MI 10. Cardiac transplant within the last 12 months 11. Pregnancy 12. Patient with peripheral Edema 13. Patient with Cardiac Arrhythmia

Design outcomes

Primary

MeasureTime frame
To study and compare efficacy of: 1.Vitamin D3 with Magnesium Glycinate therapy. 2.Cilnidipine + Telmisartan therapy. 3.Vitamin D3 + Magnesium Glycinate + Cilnidipine + Telmisartan therapy. for reduction in severity of COVID-19 disease using non-invasive measurement of Arterial Stiffness as a clinical marker Timepoint: The Pulse wave velocity in both groups will be evaluated on Day 1, 3, 5 and at discharge or day 7 or on the day of clinical deterioration whichever is earlier.—

Secondary

MeasureTime frame
1. To compare the effect of both therapies on the rate of recovery of COVID- 19 patients 2. To compare the effect of both therapies on the length of hospital stay of each patient Timepoint: Day 7 or at discharge—

Countries

India

Contacts

Public ContactDrNeeraj Kumar

AIIMS Patna

drneerajk@aiimspatna.org8210104972

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026